Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.57), $0.03 worse than the analyst estimate of ($0.54). Revenue for the quarter came in at $39.8 million versus the consensus estimate of $45.92 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.